Depression is a widespread and devastating mental illness and the search for rapid-acting
antidepressants remains critical. There is now exciting evidence that the psychedelic …

Psilocybin shows efficacy to alleviate depression in human clinical trials for six or more
months after only one or two treatments. Another hallucinogenic drug, esketamine, has …

Psychedelic compounds have shown extraordinary potential in treating a wide range of
neuropsychiatric disorders. Psilocybin, for example, has now been shown in several clinical …

Therapeutic deficiencies with monoaminergic antidepressants invites the need to identify
and develop novel rapid-acting antidepressants. Hitherto, ketamine and esketamine are …

Psilocybin and other 5-hydroxytryptamine 2A agonist classic psychedelics have been used
for centuries as sacraments within indigenous cultures. In the mid-twentieth century they …

There is a serious need for novel therapies that treat individuals with depression, including
major depressive disorder (MDD) and treatment-resistant depression (TRD). An emerging …

The main psychedelic component of magic mushrooms is psilocybin, which shows promise
as a treatment for depression and other mental disorders. Psychedelic effects are believed …

Objective: Psilocybin is a serotonin receptor agonist with a therapeutic potential for treatment-
resistant depression and other psychiatric illnesses. We investigated whether the …

While correlations between drug-induced cortisol elevation, self-reported anxiety, and
treatment outcomes have been reported for human studies during psilocybin-assisted …

Major depressive disorder (MDD) is a chronic relapsing psychiatric disorder. Conventional
antidepressants usually require several weeks of continuous administration to exert …